These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 17632511)

  • 1. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.
    Sobacchi C; Frattini A; Guerrini MM; Abinun M; Pangrazio A; Susani L; Bredius R; Mancini G; Cant A; Bishop N; Grabowski P; Del Fattore A; Messina C; Errigo G; Coxon FP; Scott DI; Teti A; Rogers MJ; Vezzoni P; Villa A; Helfrich MH
    Nat Genet; 2007 Aug; 39(8):960-2. PubMed ID: 17632511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations.
    Guerrini MM; Sobacchi C; Cassani B; Abinun M; Kilic SS; Pangrazio A; Moratto D; Mazzolari E; Clayton-Smith J; Orchard P; Coxon FP; Helfrich MH; Crockett JC; Mellis D; Vellodi A; Tezcan I; Notarangelo LD; Rogers MJ; Vezzoni P; Villa A; Frattini A
    Am J Hum Genet; 2008 Jul; 83(1):64-76. PubMed ID: 18606301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant autosomal recessive osteopetrosis caused by spontaneous mutation of murine Rank.
    Kapur RP; Yao Z; Iida MH; Clarke CM; Doggett B; Xing L; Boyce BF
    J Bone Miner Res; 2004 Oct; 19(10):1689-97. PubMed ID: 15355564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infantile malignant, autosomal recessive osteopetrosis: the rich and the poor.
    Villa A; Guerrini MM; Cassani B; Pangrazio A; Sobacchi C
    Calcif Tissue Int; 2009 Jan; 84(1):1-12. PubMed ID: 19082854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF.
    Douni E; Rinotas V; Makrinou E; Zwerina J; Penninger JM; Eliopoulos E; Schett G; Kollias G
    Hum Mol Genet; 2012 Feb; 21(4):784-98. PubMed ID: 22068587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations within the TNF-like core domain of RANKL impair osteoclast differentiation and activation.
    Cheng T; Pavlos NJ; Wang C; Tan JW; Lin JM; Cornish J; Zheng MH; Xu J
    Mol Endocrinol; 2009 Jan; 23(1):35-46. PubMed ID: 19008464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The osteoclast-not always guilty.
    Mundy GR; Edwards JR
    Cell Metab; 2007 Sep; 6(3):157-9. PubMed ID: 17767902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor.
    Nicholls BM; Bredius RG; Hamdy NA; Gerritsen EJ; Lankester AC; Hogendoorn PC; Nesbitt SA; Horton MA; Flanagan AM
    J Bone Miner Res; 2005 Dec; 20(12):2264-70. PubMed ID: 16294279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoclast-poor osteopetrosis.
    Sobacchi C; Abinun M
    Bone; 2022 Nov; 164():116541. PubMed ID: 36031188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteopetrosis rescue upon RANKL administration to Rankl(-/-) mice: a new therapy for human RANKL-dependent ARO.
    Lo Iacono N; Blair HC; Poliani PL; Marrella V; Ficara F; Cassani B; Facchetti F; Fontana E; Guerrini MM; Traggiai E; Schena F; Paulis M; Mantero S; Inforzato A; Valaperta S; Pangrazio A; Crisafulli L; Maina V; Kostenuik P; Vezzoni P; Villa A; Sobacchi C
    J Bone Miner Res; 2012 Dec; 27(12):2501-10. PubMed ID: 22836362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare disease.
    Lo Iacono N; Pangrazio A; Abinun M; Bredius R; Zecca M; Blair HC; Vezzoni P; Villa A; Sobacchi C
    Clin Dev Immunol; 2013; 2013():412768. PubMed ID: 23762088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insertion Mutation in Tnfrsf11a Causes a Paget's Disease-Like Phenotype in Heterozygous Mice and Osteopetrosis in Homozygous Mice.
    Alonso N; Wani S; Rose L; Van't Hof RJ; Ralston SH; Albagha OME
    J Bone Miner Res; 2021 Jul; 36(7):1376-1386. PubMed ID: 33724536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.
    Crockett JC; Mellis DJ; Scott DI; Helfrich MH
    Osteoporos Int; 2011 Jan; 22(1):1-20. PubMed ID: 20458572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANK-dependent autosomal recessive osteopetrosis: characterization of five new cases with novel mutations.
    Pangrazio A; Cassani B; Guerrini MM; Crockett JC; Marrella V; Zammataro L; Strina D; Schulz A; Schlack C; Kornak U; Mellis DJ; Duthie A; Helfrich MH; Durandy A; Moshous D; Vellodi A; Chiesa R; Veys P; Lo Iacono N; Vezzoni P; Fischer A; Villa A; Sobacchi C
    J Bone Miner Res; 2012 Feb; 27(2):342-51. PubMed ID: 22271396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
    Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
    J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo.
    Henriksen K; Gram J; Høegh-Andersen P; Jemtland R; Ueland T; Dziegiel MH; Schaller S; Bollerslev J; Karsdal MA
    Am J Pathol; 2005 Nov; 167(5):1341-8. PubMed ID: 16251418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis.
    Frattini A; Orchard PJ; Sobacchi C; Giliani S; Abinun M; Mattsson JP; Keeling DJ; Andersson AK; Wallbrandt P; Zecca L; Notarangelo LD; Vezzoni P; Villa A
    Nat Genet; 2000 Jul; 25(3):343-6. PubMed ID: 10888887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SNX10 mutations define a subgroup of human autosomal recessive osteopetrosis with variable clinical severity.
    Pangrazio A; Fasth A; Sbardellati A; Orchard PJ; Kasow KA; Raza J; Albayrak C; Albayrak D; Vanakker OM; De Moerloose B; Vellodi A; Notarangelo LD; Schlack C; Strauss G; Kühl JS; Caldana E; Lo Iacono N; Susani L; Kornak U; Schulz A; Vezzoni P; Villa A; Sobacchi C
    J Bone Miner Res; 2013 May; 28(5):1041-9. PubMed ID: 23280965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
    Sankar U; Patel K; Rosol TJ; Ostrowski MC
    J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties.
    Chu K; Snyder R; Econs MJ
    J Bone Miner Res; 2006 Jul; 21(7):1089-97. PubMed ID: 16813529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.